Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

1. Statins for the primary prevention of cardiovascular events

HISTORICAL AND CURRENT STATIN USE IN BELGIUM 3.1 Introduction Statins (also known as HMG-CoA reductase inhibitors) are a class of lipid- lowering medications. Statins proved to reduce the relative risk for cardiovascular disease (CVD), CVD events and mortality similarly in all individuals, but the absolute risk reduction is much greater in those who are at high risk of CVD events. Statins are used both in the primary and secondary prevention of CVD. Clinical practice guidelines generally recommend (...) the full responsibility of the KCE. Publication date: 15 January 2019 Domain: Health Technology Assessment (HTA) MeSH: Hydroxymethylglutaryl-CoA Reductase Inhibitors; Cardiovascular Diseases; Primary prevention; Costs and Cost Analysis. NLM Classification: WG 120 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2019/10.273/07 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications. How

2019 Belgian Health Care Knowledge Centre

2. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

of these events is a priority. Overall, in patients for whom statin treatment is recommended by current guidelines, the benefits greatly outweigh the risks. The development and use of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) class of drugs, which, according to the prescribing information, reduce low-density lipoprotein cholesterol (LDL-C) on average by 55% to 60% at the maximal doses of the most potent statins, has had a major impact in reducing the incidence (...) metabolites, which is equivalent to taking a larger dose, and thereby increases the risk of myopathy/rhabdomyolysis. The most important pharmacokinetic difference among the statins is that only lovastatin, simvastatin, and atorvastatin are cytochrome P450 3A4 (CYP3A4) substrates and consequently are vulnerable to drug interactions with CYP3A4 inhibitors, some of which are commonly used. Because of the high first-pass metabolism of lovastatin and simvastatin, the effects of CYP3A4 inhibitors

2019 American Gastroenterological Association Institute

4. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. Full Text available with Trip Pro

Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. Poststroke osteoporosis and consequent fractures increase the risk of morbidity and mortality and cause considerable socioeconomic burden.To evaluate the association between statin use and risks of osteoporosis and fracture in stroke patients.Population-based propensity score‒matched cohort study.Taiwan's National Health Insurance Research Database.Patients newly diagnosed with a stroke between 2000 (...) and 2012 were identified. After propensity score matching, 5254 patients were included, with 2627 patients in the statin and nonstatin cohorts, respectively.Hazard ratios (HRs) for poststroke osteoporosis, hip fracture, and vertebral fracture (together, the primary outcome) were calculated using Cox proportional hazards regression models according to statin use status.Poststroke statin use was associated with a lower overall risk of the primary outcome [adjusted hazard ratio (aHR) = 0.66; P < 0.001

2018 Journal of Clinical Endocrinology and Metabolism

5. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

enhanced gene expression. Many of the same transcription factors involved in the upregulation of CYP450 enzymes (eg, constitutive androstane receptor and pregnane X receptor) also enhance the expression of P-gp. Although reports vary, atorvastatin, lovastatin, pitavastatin, and simvastatin have been implicated as both P-gp substrates and inhibitors. Common P-gp substrates, inducers, and inhibitors that affect statin metabolism are given in . , , Table 3. Common P-gp Substrates, Inhibitors, and Inducers (...) Associated With the CYP450 Enzymes Affecting Statin Metabolism , , Enzyme Statin Substrates Inhibitors Inducers CYP2C9 Fluvastatin, rosuvastatin (also CYP2C19, minor) Amiodarone, capecitabine, etravirine, fluconazole, fluvoxamine, fluvastatin,ketoconazole, metronidazole, miconazole, oxandrolone, sulfamethoxazole/trimethoprim, voriconazole, zafirlukast Carbamazepine, phenobarbital, phenytoinrifampin CYP3A4 Atorvastatin, lovastatin, simvastatin Amiodarone,amlodipine, aprepitant, atorvastatin, bicalutamide

2016 American Heart Association

6. Statin

Statin Top results for statin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for statin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

7. Cholesterol: slightly higher risk of type 2 diabetes with all statins

Cholesterol: slightly higher risk of type 2 diabetes with all statins Prescrire IN ENGLISH - Spotlight ''Cholesterol: slightly higher risk of type 2 diabetes with all statins'', 1 January 2017 {1} {1} {1} | | > > > Cholesterol: slightly higher risk of type 2 diabetes with all statins Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Cholesterol (...) : slightly higher risk of type 2 diabetes with all statins Several large-scale studies have revealed an increased risk of type 2 diabetes in patients taking a statin. Statins are widely used to lower cholesterol, in the hope of reducing the risk of premature death and major cardiovascular events (myocardial infarction, ischaemic stroke). A review has been carried out of 13 studies which included patient follow-up for at least one year. Some 91,000 non-diabetic participants were monitored for 4 years

2017 Prescrire

8. Should patients on statins take Coenzyme Q10 supplementation to reduce the risk of statin-induced myopathy?

Should patients on statins take Coenzyme Q10 supplementation to reduce the risk of statin-induced myopathy? Should patients on statins take Coenzyme Q10 supplementation to reduce the risk of statin-induced myopathy? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · 28th March 2019 · UKMi This updated Medicines Q&A evaluates the available evidence on the use of coenzyme Q10 supplementation to reduce the risk of statin-induced myopathy. There is some (...) limited evidence which suggests that CoQ10 supplementation with statin treatment may improve statin-associated muscle symptoms. However, CoQ10 supplementation does not appear to have any effect on CK levels though data on this are also limited. More information is needed about the cause of statin-induced myopathy including about how exogenous CoQ10 affects endogenous tissue levels and whether restoring these levels results in a clinical reduction of muscle symptoms. Most importantly, studies which

2019 Specialist Pharmacy Services

9. Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use

Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Prescrire IN ENGLISH - Spotlight ''Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use '', 1 July 2018 {1} {1} {1} | | > > > Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use FEATURED REVIEW Given its weak efficacy and sometimes serious adverse effects, the harm-benefit balance of statin therapy in primary cardiovascular prevention is uncertain and close to neutral. Much else can be done to reduce

2018 Prescrire

10. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. Full Text available with Trip Pro

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. To assess whether statin treatment is associated with a reduction in atherosclerotic cardiovascular disease (CVD) and mortality in old and very old adults with and without diabetes.Retrospective cohort study.Database of the Catalan primary care system (SIDIAP), Spain, 2006-15.46 864 people aged 75 years or more without clinically (...) recognised atherosclerotic CVD. Participants were stratified by presence of type 2 diabetes mellitus and as statin non-users or new users.Incidences of atherosclerotic CVD and all cause mortality compared using Cox proportional hazards modelling, adjusted by the propensity score of statin treatment. The relation of age with the effect of statins was assessed using both a categorical approach, stratifying the analysis by old (75-84 years) and very old (≥85 years) age groups, and a continuous analysis

2018 BMJ

11. Non-Statin Therapies For LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

-effectiveness estimates were also provided. These considerations may help clinicians and patients to quantify the potential bene?ts of adding ezetimibe therapy or PCSK9 inhibitors in secondary pre- vention and in primary prevention among patients with LDL-C$190 mg/dL. Based on the important evidence of signi?cant bene?tin cardiovascular event reduction with the addition of evolo- cumab to maximally tolerated statin, with or without eze- timibe, and other new perspectives reviewed in the previous text (...) interactions, and consider patient prefer- ences. The interindividual variability in response to evo- locumab has not been reported. It is reasonable to engage in aclinician–patientdiscussionwith consideration of net risk reduction bene?ts of a PCSK9 inhibitor, cost, administration by subcutaneous injection, every 14-day or monthly dosing schedule, and storage requirements (refrigeration). If a PCSK9 inhibitor is prescribed, clini- cians should continue maximally tolerated statin and monitoring

2017 American College of Cardiology

12. Diagnosis of osteoporosis in statin-treated patients is dose-dependent Full Text available with Trip Pro

Diagnosis of osteoporosis in statin-treated patients is dose-dependent Whether HMG-CoA-reductase inhibition, the main mechanism of statins, plays a role in the pathogenesis of osteoporosis, is not entirely known so far. Consequently, this study was set out to investigate the relationship of different kinds and dosages of statins with osteoporosis, hypothesising that the inhibition of the synthesis of cholesterol could influence sex-hormones and therefore the diagnosis of osteoporosis.Medical (...) claims data of all Austrians from 2006 to 2007 was used to identify all patients treated with statins to compute their daily defined dose averages of six different types of statins. We applied multiple logistic regression to analyse the dose-dependent risks of being diagnosed with osteoporosis for each statin individually.In the general study population, statin treatment was associated with an overrepresentation of diagnosed osteoporosis compared with controls (OR: 3.62, 95% CI 3.55 to 3.69, p<0.01

2019 EvidenceUpdates

13. Statin use does not protect from fractures: the healthy adherer effect is a plausible explanation in observational studies Full Text available with Trip Pro

Hydroxymethylglutaryl-CoA Reductase Inhibitors IM Osteoporos Int. 2017 Sep;28(9):2737-2738 28555284 Osteoporos Int. 2017 Jan;28(1):47-57 27888285 Fractures, Bone Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Medication Adherence 2017 01 13 2017 04 26 2017 5 31 6 0 2018 9 11 6 0 2017 5 31 6 0 ppublish 28555283 10.1007/s00198-017-4069-1 10.1007/s00198-017-4069-1 PMC5550523 J Bone Miner Res. 2004 May;19(5):737-44 15068496 BMJ. 2006 Jul 1;333(7557):15 16790458 Osteoporos Int. 2017 Jan;28(1):47-57 27888285 (...) Statin use does not protect from fractures: the healthy adherer effect is a plausible explanation in observational studies 28555283 2018 09 10 2018 12 02 1433-2965 28 9 2017 09 Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Osteoporos Int Statin use does not protect from fractures: the healthy adherer effect is a plausible explanation in observational studies. 2739

2017 Osteoporosis International

14. Primary Prevention With Statins in the Elderly. Full Text available with Trip Pro

Primary Prevention With Statins in the Elderly. The burden of atherosclerotic cardiovascular disease (ASCVD) in high-income countries is mostly borne by the elderly. With increasing life expectancy, clear guidance on sensible use of statin therapy to prevent a first and potentially devastating ASCVD event is critically important to ensure a healthy aging population. Since 2013, 5 major North American and European guidelines on statin use in primary prevention of ASCVD have been released (...) by the American College of Cardiology/American Heart Association, the UK National Institute for Health and Care Excellence, the Canadian Cardiovascular Society, U.S. Preventive Services Task Force, and the European Society of Cardiology/European Atherosclerosis Society. Guidance on using statin therapy in primary ASCVD prevention in the growing elderly population (>65 years of age) differs markedly. The authors discuss the discrepant recommendations, place them into the context of available evidence

2018 Journal of the American College of Cardiology

15. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial Full Text available with Trip Pro

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY DM-DYSLIPIDEMIA trial (NCT02642159).The UC options (no additional lipid-lowering (...) non-HDL cholesterol to a greater degree within each UC stratum at week 24. The incidence of treatment-emergent adverse events was 68.4% (alirocumab) and 66.4% (UC). No clinically meaningful effect on glycated haemoglobin, or change in number of glucose-lowering agents, was seen.In individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin, alirocumab showed superiority to UC in non-HDL cholesterol reduction and was generally well tolerated.© 2018 The Authors. Diabetes, Obesity

2018 EvidenceUpdates

16. Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction Full Text available with Trip Pro

Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction The risk for a first myocardial infarction (MI) in people with diabetes has been shown to be as high as the risk for a new MI in non-diabetic patients with a prior MI. Consequently, risk-reducing statin therapy is recommended for nearly all patients with diabetes 40 years of age or older, regardless of cholesterol level. The purpose of this study was to assess the recommended and real-life (...) use of statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in diabetic patients who develop ASCVD.In a cross-sectional multicenter study of consecutive patients without previous ASCVD hospitalized with a first MI in 2010-2012, we obtained information on diabetic status, statin use, and cardiovascular risk factors prior to MI.The study population consisted of 1622 patients with first MI (63 % men), 228 of whom had known diabetes before MI. All but three of the diabetic

2016 Cardiovascular diabetology

17. Effectiveness of statin therapy in adults with coronary heart disease Full Text available with Trip Pro

2004; 164(13): 1427-1436 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Adult; Biomarkers /blood; Cholesterol, LDL /drug effects; Coronary Disease /blood /drug therapy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors /administration & Male; Meta-Analysis as Topic; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; dosage /therapeutic use AccessionNumber 12004008578 Date bibliographic record published 31 (...) Effectiveness of statin therapy in adults with coronary heart disease Effectiveness of statin therapy in adults with coronary heart disease Effectiveness of statin therapy in adults with coronary heart disease Wilt T J, Bloomfield H E, MacDonald R, Nelson D, Rutks I, Ho M, Larsen G, McCall A, Pineros S, Sales A CRD summary The review assessed the effectiveness of statins in treating coronary heart disease (CHD) and in preventing CHD in those at high risk. The authors found that the use

2004 DARE.

18. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Full Text available with Trip Pro

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk.To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes.Posttrial follow-up

2017 JAMA cardiology Controlled trial quality: predicted high

19. Statins in secondary cardiovascular prevention

Statins in secondary cardiovascular prevention Prescrire IN ENGLISH - Spotlight ''Statins in secondary cardiovascular prevention'', 1 September 2017 {1} {1} {1} | | > > > Statins in secondary cardiovascular prevention Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in secondary cardiovascular prevention FEATURED REVIEW What is the evidence (...) for the efficacy of statins in secondary cardiovascular prevention? In which situations are they effective? What are their harms? To answer these questions, we reviewed the available evidence using the standard Prescrire methodology. Free abstract available here; full review (8 pages) available for download by subscribers. Abstract For patients who have already had a cardiovascular event or who have stable angina or peripheral artery disease, the prevention of cardiovascular events ("secondary prevention

2017 Prescrire

20. Real-life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study. (Abstract)

Real-life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study. The benefits of initiating statins in the elderly remains debated. We evaluated the effects of initiating statins in the elderly, according to cardiovascular risk.This population-based cohort study used data of the representative sample of the French health care system database for the 2008-2015 period. New users of statins, aged 75 years and older, were dynamically included (...) in the cohort and matched 1:1 to statin nonusers on age, sex, numbers of different drugs dispensed and medical consultations, and cardiovascular history. Patients were classified into 3 cardiovascular risk groups: secondary prevention (history of coronary heart disease), primary prevention with modifiable risk factors (diabetes or cardiovascular medications), and primary prevention without modifiable risk factors (none of the above). Effect of cumulative use of statins on occurrence of acute coronary

2019 American Journal of Medicine